- Home
- APVO vs NCNA Comparison
APVO vs NCNA Comparison
Compare APVO & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- NCNA
- Stock Information
- Founded
- APVO 2016
- NCNA 1997
- Country
- APVO United States
- NCNA United Kingdom
- Employees
- APVO N/A
- NCNA N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- NCNA Health Care
- Exchange
- APVO Nasdaq
- NCNA Nasdaq
- Market Cap
- APVO 4.1M
- NCNA 4.5M
- IPO Year
- APVO N/A
- NCNA 2017
- Fundamental
- Price
- APVO $3.23
- NCNA $0.09
- Analyst Decision
- APVO Strong Buy
- NCNA Buy
- Analyst Count
- APVO 1
- NCNA 2
- Target Price
- APVO $5,920.00
- NCNA $25.00
- AVG Volume (30 Days)
- APVO 6.6M
- NCNA 319.9M
- Earning Date
- APVO 08-07-2025
- NCNA 08-14-2025
- Dividend Yield
- APVO N/A
- NCNA N/A
- EPS Growth
- APVO N/A
- NCNA N/A
- EPS
- APVO N/A
- NCNA N/A
- Revenue
- APVO N/A
- NCNA N/A
- Revenue This Year
- APVO N/A
- NCNA N/A
- Revenue Next Year
- APVO N/A
- NCNA N/A
- P/E Ratio
- APVO N/A
- NCNA N/A
- Revenue Growth
- APVO N/A
- NCNA N/A
- 52 Week Low
- APVO $2.81
- NCNA $0.03
- 52 Week High
- APVO $485.37
- NCNA $10.79
- Technical
- Relative Strength Index (RSI)
- APVO 34.28
- NCNA 41.41
- Support Level
- APVO $2.81
- NCNA $0.07
- Resistance Level
- APVO $13.11
- NCNA $0.10
- Average True Range (ATR)
- APVO 1.10
- NCNA 0.03
- MACD
- APVO 0.30
- NCNA 0.01
- Stochastic Oscillator
- APVO 4.08
- NCNA 25.70
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.